Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
Price : $35 *
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 26 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 May 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
- 19 Apr 2018 New trial record